Efficacy of local Bacillus Calmette-Guérin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy.
The efficacy of local immunotherapy with Keyhole-Limpet Hemocyanin (KLH) and Bacillus Calmette-Guérin (BCG) in preventing recurrence of superficial bladder cancer (stages pTa to pT1; grades 1 to 3) was checked in 96 patients. All tumours were resected and all patients were presumed to be free of malignant disease at initiation of prophylactic KLH instillations. Before starting KLH instillations (20 mg/administration week for 6 weeks, followed by regular (bi)monthly instillations for 3 years altogether) all patients were intracutaneously immunized with 1 mg KLH. Tumour relapse under this therapeutic schedule was the indication for BCG instillations (120 mg BCG-Connaught; administration in analogy to KLH treatment). This study has proved that (1) prophylactic KLH treatment reduced superficial bladder cancer relapse rate after surgical intervention without considerable local/systemic side effects and (2) local BCG-administration was therapeutically effective in relapsing/progressive disease under KLH treatment. There were, however, pronounced side effects.
Jurincic-Winkler
C
C
Urologische Klinik, Allgemeines Krankenhaus Celle.
Engelmann
U
U
Beuth
J
J
Klippel
K F
KF
D000276:Adjuvants, Immunologic; D000368:Aged; D005260:Female; D006433:Hemocyanins / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D009163:Mycobacterium bovis / Q000276:immunology*; D012008:Recurrence; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D000276:Adjuvants, Immunologic; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin